Conference Coverage
Novel AI-Based Prognostication Method Predicts Long-Term Progression-Free Survival in HR-Positive, HER2-Negative Early Breast Cancer
12/18/2024
Omar El Nahhas, PhD, Uniklinik RWTH Aachen, Aachen, Germany, discusses study results which demonstrated that StratifAI BReast, a novel artificial intelligence (AI)-based prognostication method, was predictive of 12-year progression-free survival (PFS) and validated molecular risk assessment in a cohort of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Source:
El Nahhas OSM, Khader F, Paul E, et al. Deep learning based tumor microenvironment signature predicts progression free survival in early stage hormone receptor positive and HER2 negative breast cancer. Presented at the 2024 San Antonio Breast Cancer Symposium. San Antonio, Texas. Abstract P20618
